Transition From Alendronate to Romosozumab (AMG 785)

Summary

The purpose of this study is to estimate the percent change from baseline in lumbar spine bone mineral density (BMD) following multiple-dose administrations of romosozumab in postmenopausal women with low BMD previously treated with alendronate.

Timeline

Start

2012-03-30

Primary completion

2012-11-21

Completion

2012-11-21

Drugs

Indications